{"title":"中欧和东欧的前列腺癌：基于全球疾病负担研究（1990-2021年）的负担、趋势和未来预测的综合区域分析","authors":"Prakasini Satapathy, Shilpa Gaidhane, Gaurav Sanghvi, Subbulakshmi Ganesan, Swati Mishra, Krishnakumar Samikan, Ashutosh Jena, Mahendra Singh, Sanjit Sah, Shubham Kumar, Khang Wen Goh, Muhammed Shabil","doi":"10.1080/14737140.2025.2483853","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to assess the burden of prostate cancer (PCa) in Central and Eastern Europe (CEE) by analyzing historical trends, evaluating the current burden, and forecasting future trends.</p><p><strong>Methods: </strong>This study uses data from the Global Burden of Disease (GBD) study spanning 1990-2021 to analyze PCa trends in CEE. We assessed age-standardized rates (ASRs) of PCa to identify trend changes through joinpoint regression analysis, explored regional disparities using QGIS software, and made projections for 2031 using the ARIMA model.</p><p><strong>Results: </strong>Eastern Europe experienced greater changes across health metrics compared to Central Europe, with higher average annual percentage change values for incidence, prevalence, mortality, and DALYs rates. In 2021, Lithuania and Estonia recorded the highest PCa prevalence rates, while Estonia had the highest total percentage change (240.3). Estonia and Latvia also had the highest mortality rates (34.1 and 33.6 per 100,000, respectively). CEE's prevalence rates are projected to remain stable.</p><p><strong>Conclusion: </strong>The findings highlight significant regional disparities in the burden of prostate cancer in CEE. Efforts to address these disparities should focus on enhancing diagnostic programs and treatment access, particularly in Eastern Europe, to reduce the ongoing burden of PCa in the region.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostate cancer in central and Eastern Europe: a comprehensive regional analysis of burden, trends, and future projections based on the global burden of disease study (1990-2021).\",\"authors\":\"Prakasini Satapathy, Shilpa Gaidhane, Gaurav Sanghvi, Subbulakshmi Ganesan, Swati Mishra, Krishnakumar Samikan, Ashutosh Jena, Mahendra Singh, Sanjit Sah, Shubham Kumar, Khang Wen Goh, Muhammed Shabil\",\"doi\":\"10.1080/14737140.2025.2483853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aims to assess the burden of prostate cancer (PCa) in Central and Eastern Europe (CEE) by analyzing historical trends, evaluating the current burden, and forecasting future trends.</p><p><strong>Methods: </strong>This study uses data from the Global Burden of Disease (GBD) study spanning 1990-2021 to analyze PCa trends in CEE. We assessed age-standardized rates (ASRs) of PCa to identify trend changes through joinpoint regression analysis, explored regional disparities using QGIS software, and made projections for 2031 using the ARIMA model.</p><p><strong>Results: </strong>Eastern Europe experienced greater changes across health metrics compared to Central Europe, with higher average annual percentage change values for incidence, prevalence, mortality, and DALYs rates. In 2021, Lithuania and Estonia recorded the highest PCa prevalence rates, while Estonia had the highest total percentage change (240.3). Estonia and Latvia also had the highest mortality rates (34.1 and 33.6 per 100,000, respectively). CEE's prevalence rates are projected to remain stable.</p><p><strong>Conclusion: </strong>The findings highlight significant regional disparities in the burden of prostate cancer in CEE. Efforts to address these disparities should focus on enhancing diagnostic programs and treatment access, particularly in Eastern Europe, to reduce the ongoing burden of PCa in the region.</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2483853\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2483853","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prostate cancer in central and Eastern Europe: a comprehensive regional analysis of burden, trends, and future projections based on the global burden of disease study (1990-2021).
Objectives: This study aims to assess the burden of prostate cancer (PCa) in Central and Eastern Europe (CEE) by analyzing historical trends, evaluating the current burden, and forecasting future trends.
Methods: This study uses data from the Global Burden of Disease (GBD) study spanning 1990-2021 to analyze PCa trends in CEE. We assessed age-standardized rates (ASRs) of PCa to identify trend changes through joinpoint regression analysis, explored regional disparities using QGIS software, and made projections for 2031 using the ARIMA model.
Results: Eastern Europe experienced greater changes across health metrics compared to Central Europe, with higher average annual percentage change values for incidence, prevalence, mortality, and DALYs rates. In 2021, Lithuania and Estonia recorded the highest PCa prevalence rates, while Estonia had the highest total percentage change (240.3). Estonia and Latvia also had the highest mortality rates (34.1 and 33.6 per 100,000, respectively). CEE's prevalence rates are projected to remain stable.
Conclusion: The findings highlight significant regional disparities in the burden of prostate cancer in CEE. Efforts to address these disparities should focus on enhancing diagnostic programs and treatment access, particularly in Eastern Europe, to reduce the ongoing burden of PCa in the region.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
